Ziphius Vaccines is a global biopharmaceutical company dedicated to develop next-generation vaccines using its proprietary self-amplifying RNA-platform for the prevention of infectious diseases. The mission is to reduce the impact of infectious diseases on global health care.
ORPHA Strategy's Principal, David Schwicker, will act as Strategic Advisor, supporting the Ziphius team with insights for business development, asset valuation, clinical and value evidence generation, patient- & caregiver-relevant outcomes and leveraging real-world evidence to accelerate the company's innovative programs.
BIOPHARMA GLOBAL Specialists Consulting for FDA & EMA Orphan Drug Development and Designations for Rare Diseases
A US-based corporation that operates as a not-for-profit, BioPharma Global offers FDA & EMA regulatory affairs and a complete suite of professional services to address the needs of emerging and growing biotech companies globally dedicated to rare disease research.
BioPharma Global specifically focusses on orphan drug designations and accelerated marketing authorisations, including FDA's expedited programs and EMA's PRIME.
We provide creative and analytically rigorous advice on strategic problems and devise effective solutions to drive our clients' programmes forward. We do this through collaboration, by channelling and merging our expertise with that of our clients. Our approach has been honed in more than 25 years of consulting experience and will flexibly adapt to specific and unique challenges. Please contact us today to start a strategic discussion about early market access strategy.
ORPHA Strategy Consulting
Phase IV Programs LLC
David Schwicker, Principal
4051 Basle, Switzerland
Tel: +43 676 362 9571